GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (LSE:GNS) » Definitions » Net Change in Cash

Genus (LSE:GNS) Net Change in Cash : £-0.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Genus Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Genus's Net Change in Cash for the six months ended in Dec. 2023 was £5.7 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.3 Mil.

Genus Net Change in Cash Historical Data

The historical data trend for Genus's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus Net Change in Cash Chart

Genus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 10.80 4.70 -7.20 -2.50

Genus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -7.10 3.50 -6.00 5.70

Genus Net Change in Cash Calculation

Genus's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=50.4+-30.9+-18.2+-3.8
=-2.5

Genus's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=6+-8.7+9.3+-0.9
=5.7

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genus Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Genus's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Genus (LSE:GNS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (LSE:GNS) » Definitions » Net Change in Cash
Comparable Companies
LSE:ONT LSE:PRTC LSE:BVXP LSE:OXB LSE:HVO LSE:AVCT LSE:4BB LSE:FUM LSE:SCLP LSE:FARN OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
GENSF:USA GNSl:UK GBE:Germany
Address
Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ
Website
https://www.genusplc.com
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.